Otsuka Reports Results from the P-III Study of AVP-786 for Treating Agitation in Patients with Dementia Due to Alzheimer's Disease
Shots:
- Otsuka reported topline results from the P-III study assessing the efficacy, safety, and tolerability of AVP-786 to treat agitation in patients with dementia due to Alzheimer's disease
- The results did not reveal any significant difference in the mean change in the Cohen-Mansfield Agitation Inventory (CMAI) total score from baseline to wk. 12 between AVP-786 vs PBO
- Furthermore, full results for AVP-786 are pending and the company anticipates additional prespecified and exploratory analysis to establish its full potential. Otsuka plans submission of the trial findings for scientific publication at a later date
Ref: Otsuka | Image: Otsuka
Related News:- Ionis and Otsuka Sign License Agreement to Develop and Commercialize Donidalorsen for Hereditary Angioedema (HAE) in Europe
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
